Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis

0301 basic medicine myasthenia gravis bibliometric VOSviewer Immunology Publications Citespace RC581-607 United States 3. Good health Biological Factors 03 medical and health sciences Bibliometrics targeted immunotherapy Immunotherapy Immunologic diseases. Allergy Immunosuppressive Agents
DOI: 10.3389/fimmu.2022.998217 Publication Date: 2022-09-29T09:52:31Z
ABSTRACT
The treatment of myasthenia gravis (MG) has advanced from steroids and traditional immunosuppressants to targeted immunotherapy. Targeted immunotherapy been successfully employed in clinical practice recent years. This study aimed explore the emerging trend MG summarize knowledge structure through bibliometric methods.The Web Science Core Collection database (WoSCC) was chosen retrieve literature on for MG. Two analysis software, VOSviewer CiteSpace, online platform were mainly used evaluate contributions countries/regions, institutions, journals, authors construction visualization networks. By systematically reviewing a domain, future research developments determined. R version 4.1.2 Microsoft Excel 365 statistical analysis.A total 562 original articles 262 reviews relevant included. number publications exhibited two-phase advancement. first stage showed steady growth 1998 2016, with an annual no more than 35 publications. second revealed explosive 2017, reaching peak 2020. United States ranked publications, citations, h-index. author highest citation h-index Vincent A. And 28.03% published top 10 journals. In addition "myasthenia gravis", keyword consideration "rituximab", followed by "double-blind", which indicate hotspots gradually basic over time, especially field entered personalized precision phase. Exploration into new target molecules conducting high-quality randomized controlled trials existing biological agents are further direction.The current summarized global trends concerning Research interests research. Further investigations required urgently direct
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (70)
CITATIONS (8)